Variable | TRG 0–1 | TRG 2–3 | P | Odds Ratio (95%CI) |
---|---|---|---|---|
Training cohort | ||||
Tumor length | 0.037 | 3.19 (1.07–9.46) | ||
≦4 cm | 19 (42%) | 11 (71%) | ||
> 4 cm | 14 (58%) | 27 (29%) | ||
Circumferential extent | 0.146 | 2.65 (0.71–9.86) | ||
≦50% | 12 (36%) | 5 (13%) | ||
> 50% | 21 (64%) | 33 (87%) | ||
Normalization of post- treatment CEA Level | 0.082 | 2.81 (0.88–9.01) | ||
Normal (< 5 ng/mL) | 26 (79%) | 21 (55%) | ||
Elevated (≧5 ng/mL) | 7 (21%) | 17 (45%) | ||
CEA clearance pattern | 0.161 | 2.18 (0.73–6.44) | ||
Exponential decrease (R2≧0.9) | 19 (58%) | 12 (32%) | ||
Non-exponential decrease (R2 < 0.9) | 14 (42%) | 26 (68%) | ||
Validation cohort | ||||
Tumor length | 0.009 | 4.23 (1.43–12.50) | ||
≦4 cm | 19 (58%) | 12 (29%) | ||
> 4 cm | 14 (42%) | 30 (64%) | ||
Circumferential extent | 0.147 | 0.42 (0.13–1.35) | ||
≦50% | 9 (27%) | 18 (43%) | ||
> 50% | 24 (73%) | 24 (57%) | ||
Normalization of post- treatment CEA Level | 0.884 | 0.92 (0.29–2.92) | ||
Normal (< 5 ng/mL) | 23 (70%) | 23 (55%) | ||
Elevated (≧5 ng/mL) | 10 (30%) | 19 (45%) | ||
CEA clearance pattern | 0.009 | 4.37 (1.44–13.23) | ||
Exponential decrease (R2≧0.9) | 21 (64%) | 15 (36%) | ||
Non-exponential decrease (R2 < 0.9) | 12 (36%) | 27 (64%) |